Protagonist Therapeutics, Inc.
NASDAQProtagonist Therapeutics enters the post-earnings window with a meaningful gap between what the numbers delivered and what the options market had priced for disaster. The company reported Q1 2026 results on May 5, beating EPS estimates by $0.54 and posting revenue of $56.4 million against a consensus of $16.3 million. That is not a modest beat — it is a blowout. Yet the stock edged…
Snapshot as of 22 Jun 2026
Protagonist Therapeutics enters the post-earnings window with a meaningful gap between what the numbers delivered and what the options market had priced for disaster. The company reported Q1 2026 results on May 5,…
Protagonist Therapeutics heads into its May 7 Q1 earnings with options markets flashing the most defensive signal of the past year. The put/call ratio has surged to 1.48 — nearly at its 52-week high and almost two…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for PTGX — free to start on ORTEX.
Sign up for free →Open PTGX on ORTEX